Business Context and Reporting Period
This Form 8-K is filed by pSivida Corp. (not Eyepoint, Inc.) on December 23, 2009. The report addresses a material event involving the company's collaborative partner, Alimera Sciences, Inc., regarding the clinical development of the drug Iluvien for Diabetic Macular Edema.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a regulatory and clinical development milestone.
Material Changes and Events
- Clinical Trial Results: Alimera Sciences reported 24-month results from the two Phase 3 pivotal FAME Study trials for Iluvien.
- Regulatory Filing: Alimera filed a Form S-1/A with the SEC disclosing these results.
- NDA Submission Plan: Alimera plans to submit a New Drug Application (NDA) to the FDA for the low dose of Iluvien in the second quarter of 2010.
- Global Expansion: Registration filings in various European countries and Canada are planned to follow the U.S. submission.
Guidance, Outlook, and Risks
- Priority Review: Alimera intends to request Priority Review of the NDA from the FDA.
- Timeline: If Priority Review is granted, a response from the FDA is expected in the fourth quarter of 2010.
- Risk Factors: The filing incorporates by reference specific risk factors relating to the Iluvien clinical development program from Alimera's Form S-1/A (Exhibit 99.1).
Investor Verification Checklist
- Verify the specific 24-month clinical trial data for the FAME Study in Alimera's Form S-1/A.
- Confirm the exact timeline for the NDA submission in Q2 2010.
- Review the "Risk Factors" section in Exhibit 99.1 for potential regulatory or clinical setbacks.
- Monitor FDA acceptance of the Priority Review request.